Comparative Pharmacology
Head-to-head clinical analysis: FASENRA versus KEVZARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FASENRA versus KEVZARA.
FASENRA vs KEVZARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
Interleukin-6 (IL-6) receptor antagonist; sarilumab binds specifically to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling through gp130 and STAT3.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
200 mg subcutaneously once weekly.
None Documented
None Documented
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
Terminal elimination half-life ~21-22 days, supporting subcutaneous dosing every 2 weeks.
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
Primarily eliminated via reticuloendothelial system catabolism. No significant renal or biliary excretion; <1% excreted unchanged in urine or feces.
Category C
Category C
Monoclonal Antibody, Anti-Interleukin-5 Receptor
Monoclonal Antibody, IL-6 Receptor Antagonist